The Tyrosine Protein Kinase BTK pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase BTK targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase BTK pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Central Nervous System, and Dermatology which include the indications Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis (RRMS), Chronic Urticaria Or Hives, and Atopic Dermatitis (Atopic Eczema). It also reviews key players involved in Tyrosine Protein Kinase BTK targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase BTK pipeline targets constitutes close to 88 molecules. Out of which, approximately 80 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 9, 18, 21, 4, 22, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 2 molecule.
Tyrosine Protein Kinase BTK overview
Bruton’s tyrosine kinase (BTK), also known as tyrosine-protein kinase BTK, is a non-receptor tyrosine kinase enzyme that plays a critical role in the development and function of B lymphocytes, a type of white blood cell responsible for humoral immunity. BTK is encoded by the BTK gene located on the X chromosome in humans.
For a complete picture of Tyrosine Protein Kinase BTK’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
